ENDRA Life Sciences Inc Registered Shs NDRA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
ENDRA Life Sciences Reports First Quarter 2026 Financial Results and Provides Business Update
-
ENDRA Life Sciences Reports Multi-Site Validation of TAEUS® Liver Device Demonstrating MRI-like Accuracy and Reproducibility
-
ENDRA Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
-
ENDRA Life Sciences Initiates Review of Strategic Alternatives to Maximize Shareholder Value
Trading Information
- Previous Close Price
- $4.27
- Day Range
- $4.25–4.47
- 52-Week Range
- $2.96–11.96
- Bid/Ask
- $4.25 / $4.41
- Shares Outstanding
- 1.27M
- Market Cap
- $5.40M
- Volume/Avg
- 3,065 / 33,619
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
ENDRA Life Sciences Inc is engaged in the development of thermo-acoustic enhanced ultrasound (TAEUS) technology to improve the capabilities of clinical diagnostic ultrasound. The company's technology is used to measure tissue composition, including the assessment of fat in the liver, and is being developed for additional clinical applications such as tissue temperature monitoring.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Stock Style Box
- Small Value
- Total Number of Employees
- 11
- Website
- https://www.endrainc.com
Valuation
|
Metric
|
NDRA
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 2.96 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
NDRA
Financial Strength
|
Metric
|
NDRA
|
|---|---|
Quick Ratio | 0.43 |
Current Ratio | 0.64 |
Interest Coverage | — |
Quick Ratio
NDRA
Profitability
|
Metric
|
NDRA
|
|---|---|
Return on Assets (Normalized) | −215.91% |
Return on Equity (Normalized) | −441.84% |
Return on Invested Capital (Normalized) | −326.70% |
Return on Assets
NDRA
Diagnostics & Research Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Thermo Fisher Scientific Inc
TMO
| Vpqzvlsc | Vhw | $175B | |||
| Danaher Corp
DHR
| Ltkpfrxm | Tkmgx | $130B | |||
| IDEXX Laboratories Inc
IDXX
| Btqgjdyqw | Bnqg | $44B | |||
| Agilent Technologies Inc
A
| Qfbswjkd | Gtgb | $37B | |||
| Waters Corp
WAT
| Cvqdwrnld | Bfqxd | $36B | |||
| IQVIA Holdings Inc
IQV
| Bcvqxfw | Bjrcqk | $31B | |||
| Illumina Inc
ILMN
| Ngbsspz | Mcstvgk | $24B | |||
| Mettler-Toledo International Inc
MTD
| Cdtzltqg | Dxgnl | $23B | |||
| Quest Diagnostics Inc
DGX
| Scjwphpsc | Xpdlhz | $22B | |||
| Labcorp Holdings Inc
LH
| Mbhnpgypm | Kqblspz | $21B |
United States